Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 30;16(19):3361.
doi: 10.3390/cancers16193361.

The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond

Farshad Sheybaee Moghaddam  1 , Sami Dwabe  2 , Nataliya Mar  2 , Leila Safdari  3 , Navin Sabharwal  4 , Hanan Goldberg  5 , Michael Daneshvar  4 , Arash Rezazadeh Kalebasty  2   4
Affiliations
Review

The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond

Farshad Sheybaee Moghaddam et al. Cancers (Basel). .

Abstract

Radical cystectomy with lymph node dissection and urinary diversion is the gold-standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC). However, in patients who refuse cystectomy, or in whom cystectomy carries a high risk, bladder-preserving therapies remain potential options. Bladder preservation therapies can include maximal debulking transurethral resection of bladder tumor (TURBT), concurrent chemoradiation therapy, followed by cystoscopy to assess response. At this time, maximal TURBT is recommended for patients prior to the initiation of chemoradiation therapy or in patients with residual bladder tumors after the completion of chemoradiation therapy. That being said, TURBT carries significant risks such as bladder perforation, bleeding, and infection, ultimately risking delayed systemic treatment. Hence, understanding its role within trimodal therapy is crucial to avoid undue suffering in patients. Herein, we review the current literature on the impact of debulking TURBT in non-metastatic MIBC.

Keywords: TURBT; Trimodality treatment; bladder preservation; bladder-sparing; muscle-invasive bladder cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Van Rhijn B.W.G., Burger M., Lotan Y., Solsona E., Stief C.G., Sylvester R.J., Witjes J.A., Zlotta A.R. Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. Eur. Urol. 2009;56:430–442. doi: 10.1016/j.eururo.2009.06.028. - DOI - PubMed
    1. Saginala K., Barsouk A., Aluru J.S., Rawla P., Padala S.A., Barsouk A. Epidemiology of Bladder Cancer. Med. Sci. 2020;8:15. doi: 10.3390/medsci8010015. - DOI - PMC - PubMed
    1. Burger M., Catto J.W.F., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Kassouf W., Kiemeney L.A., La Vecchia C., Shariat S., et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur. Urol. 2013;63:234–241. doi: 10.1016/j.eururo.2012.07.033. - DOI - PubMed
    1. Witjes J.A., Bruins H.M., Carrión A., Cathomas R., Compérat E.M., Efstathiou J.A., Fietkau R., Gakis G. Muscle-Invasive and Metastatic Bladder Cancer. European Association of Urology; Arnhem, The Netherlands: 2024.
    1. Holzbeierlein J., Bixler B.R., Buckley D.I., Chang S.S., Holmes R.S., James A.C., Kirkby E., McKiernan J.M., Schuckman A. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO GUIDELINE (Journal of Urology 2017, 198(3), 552-559; Amended 2020, 2024) J. Urol. 2024;212:3–10. doi: 10.1097/JU.0000000000003981. - DOI - PubMed